(Albany, US) DelveInsight launched a new report on Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report1. The total incident cases ofNon-Small Cell Lung Cancer in the 7MM were 484,726 cases in 2017.2. The total incident cases of NSCLC patients by histology in Germany were observed to be 16,506 cases of squamous cell carcinoma; 26,409 cases of adenocarcinoma and 6,602 cases of large cell carcinoma in 2017.3. The total diagnosed cases of NSCLC patients by stages in the 7MM were observed to be 86,590 cases of stage I; 31,552 cases of stage II; 56,297 cases of stage IIIA; 65,410 cases of stage IIIB; and 244,876 cases of stage IV in 2017.
Key benefits of the report1. Non-Small Cell Lung Cancer market report covers a descriptive overview and comprehensive insight of the Non-Small Cell Lung Cancer Epidemiology and Non-Small Cell Lung Cancer market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Non-Small Cell Lung Cancer market report provides insights into the current and emerging therapies.3. Non-Small Cell Lung Cancer market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Non-Small Cell Lung Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-Small Cell Lung Cancer market.
Request for sample pages
“Non-Small Cell Lung Cancer Market is anticipated to grow at a CAGR of 10.7% for 2017-2030 study period.”
Lung cancer mainly commences in the lungs and may spread to lymph nodes or other organs in the body like the brain. When the cancer cells spread from one organ to another, they are known as metastases. Lung cancer is a significant disease burden on the world and the greatest cause of cancer-related death.
Lung cancer is of two types:- Small Cell Lung Cancer (SCLC) And Non-Small Cell Lung Cancer (NSCLC). NSCLC can be defined as epithelial lung cancer other than SCLC. NSCLC emerges from the epithelial cells of the lung of the central bronchi to terminal alveoli. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas and sarcomatoid carcinomas.
Non-Small Cell Lung Cancer, the most common type of lung cancer that is accounted for approximately 85% of all lung cancers. Among the NSCLC cases, squamous cell carcinoma comprised of 30% cases, adenocarcinoma comprised of 40% cases, and large-cell carcinoma comprised of 15% cases.
There are different types of treatment available for NSCLC; however, mainly ten types of standard treatment are used, which include: Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
Chemotherapy is used to stop the growth of cancer cells, either by killing the cells or by stopping their division. Targeted therapy utilizes drugs or other substances to attack specific cancer cells. These therapies usually cause less harm to healthy cells than chemotherapy or radiation therapy. Monoclonal antibodies and tyrosine kinase inhibitors are the two main types of targeted therapy being used to treat advanced, metastatic, or recurrent NSCLC. Immunotherapy uses the patients’ immune system to fight cancer. Radiation therapy uses very high-energy x-rays or other types of radiations to kill cancer cells or keep them from developing.
The launch of the emerging therapies is expected to significantly impact Non-Small Cell Lung Cancer treatment scenario in the upcoming years:-Drugs covered– Nazartinib (EGF816)– Capmatinib (INC280)– Tepmetko (tepotinib)– Merestinib– JNJ-61186372 (JNJ-6372)– Vemurafenib Plus Cobimetinib– X-396 (Ensartinib)– Tedopi (OSE2101)– Selpercatinib (LY3527723/ LOXO-292)– SAR408701– Braftovi (encorafinib) + Mektovi (binimetinib)– PADCEV (enfortumab vedotin/ASG-22ME)– Pralsetinib (BLU-667)– TAK-788: Canakinumab (ACZ885)– Avelumab (Bavencio)– Veliparib (ABT-888)– Sitravatinib (MGCD516)– Tesevatinib– Romiplostim– Cabozantinib– Sym015– AMG 510– INCMGA00012 (MGA012)– Libtayo (Cemiplimab)– Bavituximab– M7824 (Bintrafusp alfa)And many others
Key Players covered in the report are:-– Novartis Pharmaceuticals– Merck KGaA– Eli Lilly and Company– Janssen Research & Development– Hoffmann-La Roche– Xcovery– BeyondSpring Pharmaceuticals– OSE Immunotherapeutics– Sanofi– Pfizer– Astellas Pharma– Seattle Genetics– Blueprint Medicines Corporation– Takeda– AbbVie– Kadmon Corporation– Amgen– Symphogen– Regeneron Pharmaceuticals– Peregrine Pharmaceuticals– Avid Bioservices– GlaxoSmithKlineAnd many others
Table of contents1. Key Insights2. Executive Summary of NSCLC3. SWOT Analysis of NSCLC4. Non-Small Cell Lung Cancer Market Overview at a Glance5. NSCLC Disease Background and Overview6. NSCLC Diagnosis7. Non-Small Cell Lung Cancer Epidemiology and Patient Population7.1. The United States Epidemiology8. EU-5 Epidemiology8.1. Germany8.2. France8.3. Italy8.4. Spain8.5. The United Kingdom9. Japan Epidemiology10. Non-Small Cell Lung Cancer Current Treatment Practices11. Guideline of NSCLC12. Unmet Needs of NSCLC13. Key Endpoints in NSCLC Clinical Trials14. Non-Small Cell Lung Cancer Marketed Therapies14.1. Key Cross14.2. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)14.3. Imfinzi (Durvalumab): AstraZeneca14.4. Opdivo (Nivolumab): Bristol-Myers Squibb14.5. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche14.6. Keytruda (Pembrolizumab): Merck14.7. Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis14.8. Tagrisso(Osimertinib): AstraZeneca14.9. Lorbrena/Lorviqua (Lorlatinib): Pfizer14.10. Vizimpro(Dacomitinib): Pfizer14.11. Alunbrig (Brigatinib): Takeda Pharmaceuticals14.12. Alecensa (Alectinib): Hoffmann-La Roche14.13. Vitrakvi (Larotrectinib): Bayer Healthcare14.14. Portrazza (Necitumumab): Eli Lilly15. Non-Small Cell Lung Cancer Emerging Therapies15.1. Nazartinib (EGF816): Novartis Pharmaceuticals15.2. Capmatinib (INC280): Novartis Pharmaceuticals15.3. Tepmetko (tepotinib): Merck KGaA15.4. Merestinib: Eli Lilly and Company15.5. JNJ-61186372 (JNJ-6372): Janssen Research & Development15.6. Lazertinib: Yuhan Corporation/ Janssen Research & Development15.7. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche15.8. X-396 (Ensartinib): Xcovery15.9. Plinabulin: BeyondSpring Pharmaceuticals15.10. Tedopi (OSE2101): OSE Immunotherapeutics15.11. Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company15.12. SAR408701: Sanofi15.13. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer15.14. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics15.15. Pralsetinib (BLU-667): Blueprint Medicines Corporation15.16. TAK-788: Takeda15.17. Canakinumab (ACZ885): Novartis Pharmaceuticals15.18. Avelumab (Bavencio): Merck KGaA and Pfizer15.19. Veliparib (ABT-888): AbbVie15.20. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene15.21. Tesevatinib: Kadmon Corporation15.22. Romiplostim: Amgen15.23. Cabozantinib: Exelixis/Ipsen/Takeda15.24. Sym015: Symphogen15.25. AMG 510: Amgen15.26. INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited15.27. Libtayo (Cemiplimab): Regeneron Pharmaceuticals15.28. Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc15.29. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA16. NSCLC Seven Major Market Analysis17. PD-L1—Market Size18. BRAF Mutation—Market Size19. c-MET Mutation—Market Size20. EGFR Mutation—Market Size21. ALK-Mutation—Market Size22. Market Access and Reimbursement of NSCLC Therapies23. Market Drivers of NSCLC24. Market Barriers of NSCLC25. Appendix26. DelveInsight Capabilities27. Disclaimer28. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:[email protected]+919650213330SOURCE DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/